Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol - Pure Green Pharmaceuticals

Next Previous
Drug Profile

Cannabidiol - Pure Green Pharmaceuticals

Alternative Names: CBD - Pure Green Pharmaceuticals; PG-DN-20WS

Latest Information Update: 15 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pure Green Pharmaceuticals
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuropathic pain
  • Phase I Pain

Most Recent Events

  • 15 Oct 2025 Phase-I development is ongoing in Pain in USA (PO) (Pure Green Pharmaceuticals pipeline, October 2025)
  • 30 Mar 2023 Phase-I clinical trials in Pain in USA (PO) before March 2023 (Pure Green Pharmaceuticals pipeline, March 2023)
  • 30 Mar 2023 Pure Green Pharmaceuticals intends to initiate regulatory fillings in Europe, Canada and the rest of the world (before March 2023) (Pure Green Pharmaceuticals Pipeline, March 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top